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Abstract
The lack of available testing for SARS-CoV-2 has been one of the primary challenges in the 
development and implementation of a comprehensive approach to infection prevention and 
transmission in the United States (US). In response to the need for increased testing capacities 
and capabilities, the University of Louisville (UofL) Division of Infectious Diseases, Center of 
Excellence for Research in Infectious Diseases (CERID) initiated the Louisville Coronavirus 
Surveillance Program, a comprehensive approach to surveillance and testing of patients and 
healthcare workers. The first specimens were accepted on March 12, 2020 and parallel test-
ing was done using a high-capacity testing process and the Division of Infectious Diseases 
CLIA-certified laboratory to ensure concordant results. Steps in the testing process began with 
validation of the testing methods and included database development, acceptance of speci-
mens, tracking and cataloging the specimens, testing, and reporting of results. Quality metrics 
were developed and used to prevent error and facilitate rapid reporting. Between March 12, 
2020 and April 30, 2020, more than 5500 tests were performed identifying more than 850 pa-
tients and healthcare workers infected with COVID-19 in the Louisville, Kentucky area. Although 
the process used high-capacity robotics for testing procedures, the methods described here are 
applicable to settings employing a variety of laboratory testing methods.
Background
The lack of available testing for SARS-CoV-2 has been one of the primary challenges 
in the development and implementation of a comprehensive approach to infection and 
infection transmission in the United States (US). State health departments and the US 
Centers for Disease Control and Prevention (CDC) were the first, and the only, sites for 
testing in the US before mid-February. Their capacities were far less than the need and 
the demand for laboratory testing. In response to the need for increased testing capaci-
ties and capabilities, the University of Louisville (UofL) Division of Infectious Diseases, 
Center of Excellence for Research in Infectious Diseases (CERID) initiated a planning 
group aimed at development of a comprehensive approach to surveillance and testing 
of patients and healthcare workers. This approach would use the existing CERID re-
search enterprise as the platform and engage new partnerships within and outside UofL 
to build and rapidly implement a high capacity testing process for the Louisville and 
surrounding areas in Kentucky. For more than thirty years, researchers in the Division 
of Infectious Diseases at the University of Louisville have been involved in clinical re-
search, primarily in the Louisville area’s nine adult and one pediatric acute care hospi-
tals. The research program has steadily grown and matured and in 2018, elements of the 
program were aligned into a comprehensive clinical research enterprise. Figure 1 pro-
vides a graphic description of CERID and its components. Success of this novel approach 
to testing would require reliance upon existing relationships and partnerships with the 
area hospital personnel and leadership coupled with the expertise of CERID personnel 
and the organizational capacity of that research enterprise.  
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In early January 2020, Luminex Corporation reached out to the UofL Division of Infectious Diseases (ID) Laboratory 
asking to partner in development of a multiplex test for SARS-CoV-2. This partnership involved assisting with the test-
ing and validation of the real-time PCR assay on the ARIES® instrument for submission to the FDA for Emergency Use 
Authorization (EUA). This work was completed by March 11, 2020 and a white paper published describing these efforts. 
[1] Happening at the same time, in mid-February 2020, the University of Louisville’s Center for Predictive Medicine 
(UofL-CPM) received a reference strain of the SARS-CoV-2 virus from BEI resources to initiate basic research geared 
toward understanding the characteristics of the virus and develop a model system for identification. The National Bio-
containment Laboratory at the University of Texas Medical Branch in Galveston proposed that the network of eleven 
regional biocontainment laboratories in the United States focus on development of new testing methods in response 
to the outbreak and limited testing capacities. As one of the regional biocontainment laboratories in that network, the 
UofL-CPM responded to the initiative. Once the virus was successfully grown and the real-time PCR assay developed 
by CDC was implemented in the UofL-CPM, discussions began regarding how the research process might facilitate 
laboratory testing for the virus using the UofL-CPM high-capacity instrumentation. The potential for expanded ac-
cess to testing was quickly recognized as a valuable addition to the limited testing capabilities present throughout the 
Commonwealth of Kentucky and the US. This expanded testing capability formed the basis for a strategic surveillance 
approach that was developed and published for broad access through the University of Louisville Journal of Respirato-
ry Infections on March 10, 2020. [2] The following information outlines the implementation approach of the Louisville 
COVID-19 Surveillance Program (LCSP) process that began with the first specimen received on March 10, 2020.
The objectives of this manuscript are to 1) describe the steps in the Louisville COVID-19 Surveillance Program (LCSP) 
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Figure 1. University of Louisville Center of Excellence for Research in Infectious Diseases 
(CERID) Research Enterprise.
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Date CERID Activity CPM Activity
2/6/2020-2/14/2020 Permission from CDC to receive SARS-CoV-2 
virus by CPM and initiation of a surveillance 
concept within the US Regional Biosafety 
Laboratory Network using CDC PCR assay
2/14/2020 Concept development for surveillance testing for 
patients and healthcare workers.
Proposed that the CPM can make RNA prep/real 
time PCR automation for SARS-CoV2 virus with 
96 samples/run.
2/24/2020 First drafts of surveillance process protocol for 
IRB.
Development of real time PCR with control 
plasmid, harvesting and amplification of the CoV 
strain.
2/28/2020 ID lab contacted by Luminex Corporation to be 
a site evaluating ARIES platform for COVID-19 
testing.
3/3/2020 ARIES test kit validation completed and FDA 
white paper submitted
By 3/5/20, RT PCR available for use.
3/7/2020 Presentation of surveillance process to IRB
3/8/2020 Submission of Louisville COVID-19 Surveillance 
Program to IRB
3/9/2020 IRB approval #20.0225
3/10/2020 Testing of patient samples for COVID-19 in ID lab 
and CPM lab in parallel
Daily review of ID lab and CPM results, then 
results discussed with Chief Medical Officers of 
each submitting hospital
Testing of patient samples for COVID-19 in ID lab 
and CPM lab in parallel.
Submission of results to ID reviewers at evenining 
meetings held each day.
3/11/2020 Daily oral report and daily written reports provided 
to Chief Medical Officers of each submitting 
hospital
3/13/2020 Submission of first 5 positive and first 5 negative 
test samples to the KDPH State Laboratory for 
verification of results
3/14/2020 Receipt of notification of results verification from 
the KDPH State Laboratory
3/15/2020 Samples being received from 10 Louisville 
hospitals and 2 southern Indiana hospitals
By close of the day on 3/15/2020 had tested 
205 samples and identified 7 positives. 100% 
congruence between ID lab and CPM lab results.
Figure 2. Timeline of Events Relevant to Planning and Implementation of the Louisville Coronavirus 
Surveillance Program.
Approach
The process used to implement the COVID-19 surveillance included developing and testing a proof of concept for the 
process, then implementing the process continuous quality assessment and improvement at its core. 
Concept of the Testing Process 
Planning for testing for patients hospitalized in the ten Louisville area acute care hospitals began on February 22, 2020. 
A timeline of events relevant to the planning and implementation of the LCSP is shown in Figure 2.
Before receipt of the first sample for testing, a process was conceptualized that would begin with the collection of a 
sample from one of the ten Louisville area hospitals, travel through the delivery, processing and testing steps, and end 
with interpretation and sharing of results. Steps in the process were simulated to identify testing capabilities; validity, 
reliability, and capacity; process and capability gaps, opportunities for error that exist at any step, and opportunities 
for improvements and efficiencies. A member of the LCSP team transported a representative sample from one of the 
Louisville area hospitals to the COVID-19 testing center. The sample was moved from receipt, through the testing 
process, and finally to storage in a biorepository. A first-generation database able to capture patient information, spec-
imen movement, results, and biorepository storage was developed using REDCap™. Specimen handling and testing 
procedures were simulated to ensure safe and optimal laboratory practices. Interpretation of results and processes 
for communicating results and related information were tested through simulation and role-play. At each phase in the 
process, team members cataloged the steps, identified opportunities for error and efficiencies, documented proposed 
changes in the process and the impact the changes, as well as quality indicators necessary to ensure a standardized, safe 
and error-free process. On March 10, 2020, the first specimens were received for testing, signaling implementation of 
the LCSP process.
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/10 4
ULJRI Endemic Human Coronaviruses in Hospitalized Adults with Community-Acquired Pneumonia in the City of Louisville, Kentucky
Implementation of the testing process
The process for developing and implementing a surveillance testing approach using high-capacity, high-throughput in-
strumentation included the following steps: 1) test instrument validation and result verification; 2) specimen database 
development; 3) specimen movement from hospitals to the testing site; 4) data entry; 5) cataloging the specimen for 
movement to the laboratory for processing; 6) assignment of the specimen barcode; 7) specimen testing; 8) integration 
of results from the testing instrument to the specimen database; 9) analysis of test results; 10) communicating test re-
sults; and 11) development and implementation of quality measures.
1. Test Instrument validation and result verification
One of the first steps in the process involved determination of existing capabilities and capacities for testing. For more 
than twenty years, the University of Louisville Division of Infectious Diseases has operated a CLIA-certified laboratory 
focused on clinical research and diagnostic testing, serving as a reference laboratory. Luminex Corporation selected the 
laboratory as one of the five US laboratory sites to validate their ARIES® instrument and primers for submission to the 
US Food and Drug Administration (FDA) as Emergency Use Authorization (EUA) test for COVID-19. [1] The Luminex 
ARIES® test evaluated the sample for SARS-CoV-2 detection using two viral genes and an internal control (N1, N3 and 
human RNaseP). Per the FDA, the ID laboratory was then required to submit the first five positive and first five nega-
tive specimens to the Kentucky Department for Public Health Division of Laboratory Services for confirmation. This 
validation process was completed on March 13, 2020. Validation enabled the UofL ID laboratory to test up to thirty 
samples in every three-hour run using the Luminex Aires® test. At the same time, the UofL-CPM had begun testing 
the high-capacity high- throughput robotic testing machine capable of testing 176 samples in each four-hour run.  This 
process used the CDC primers N1, N2, and N3 in addition to the internal control human RNaseP. Use of the UofL-CPM 
testing capability brought immediate capacity, but there was a need to evaluate results to ensure validity. Validation was 
done by running parallel samples using both the Luminex ARIES® test and the UofL-CPM CDC primers in the first 200 
samples received. The result of this parallel testing demonstrated 100% concordance with positive and negative results. 
With this concordance, we had confidence in reliance upon the high-capacity test instrument for all surveillance test-
ing moving forward. 
2. Specimen database development
A REDCap database was developed to capture all information necessary to track the specimen from receipt to result. 
Figures 3, 4, 5, 6, and 7 show the most current five database sections developed for this project including: 1) test re-
quest form, 2) barcode, 3) laboratory/biorepository, 4) results, and 5) Louisville Coronavirus Surveillance Report. The 
initial database was improved repeatedly during the first three weeks of operation to ensure information of importance 
to the hospitals, public health, and other stakeholders was included. Individual reports were developed and made avail-
able on day one of the project, as were access portals to facility results via individual facility REDCap links. These links 
were made available to these partners after the first three weeks of operation. This approach facilitated the goal of re-
al-time access to the data for hospitals and public health.  
3. Specimen movement from hospitals to the testing site
Patient samples were collected by hospital personnel and sent to their respective laboratories for pickup by LCSP per-
sonnel. For facilities preferring to courier their samples to the testing site, LCSP was able to accept those specimens 
and move them into the process. Hospitals were asked to package each specimen in a biohazard bag with identifying 
information on the specimen container (e.g., patient label) and complete a COVID-19 specimen test request form plac-
ing it in a pocket on the outside of the biohazard bag. This form contained patient information such as name, date of 
birth, medical record number; the type of specimen (e.g., nasopharyngeal); date and time of specimen collection; and 
any other hospital-specific information important to that facility (e.g., laboratory accession number). LCSP personnel 
reported to a designated pick-up area at each hospital laboratory three to four times throughout the day (0700, 1100, 
1200, and 1700) seven days a week, to retrieve samples and transport in temperature-controlled containers back to the 
testing site. Team members wore gloves during handling of the specimen bags.  Clear plastic transport containers with 
closable lids and biohazard labels were disinfected with a healthcare-grade registered (e.g., quaternary ammonium) 
germicide following each transport event.  
4. Data entry
Upon receipt of the specimen bags, LCSP personnel entered data into REDCap by completing the test request and 
biorepository/laboratory sections. (Figures 3 and 5) The data entry process consisted of teams of two researchers and 
two quality reviewers. One researcher entered data into REDCap and the second researcher was responsible for han-
dling the specimen bag. (Image 1) The researcher handling the specimen bag provided the information from the spec-
imen test requisition form—or specimen tube label if no requisition form was available—to the researcher entering the 
data. If no test requisition form accompanied the specimen, a generic form was completed at that time. This facilitated 
data entry and quality processes. Specimen biohazard bags remained closed and the specimen tube information was 
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/10 5
ULJRI Endemic Human Coronaviruses in Hospitalized Adults with Community-Acquired Pneumonia in the City of Louisville, Kentucky
Figure 3. REDCap Database Test Request Form Page.
Figure 4. REDCap Barcode Page.
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Figure 5. REDCap Laboratory/Biorepository Page.
Figure 6. REDCap Results Page.
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Figure 7. REDCap Louisville Coronavirus Surveillance Program Report Page.
Image 1. Researchers Entering Data into REDCap From Patient Specimen.
visualized through the biohazard bag. The team member handling the closed bag wore gloves and hands were washed 
after glove removal. After completing the data entry process, the specimen tubes still inside the closed biohazard bags 
were placed back into the clear plastic lockable container and taken to the biosafety cabinet area to begin the racking 
and cataloging process. 
5. Cataloging the specimen for movement to the laboratory for processing
The racking of tubes and spreadsheet production process (cataloging) consisted of teams of two researchers (#1 and 
#2) and one quality reviewer. The laboratory cataloging process involved the use of a biosafety cabinet (BSC, Level 2) 
with controlled airflow and a protective sash that could be lowered providing a safe work environment commonly re-
ferred to as “under the hood”. Once under the BSC, the specimen bags were opened, and the specimen tubes were pre-
pared for placement in the specimen tube racks. Researcher #1 handling the specimen tubes wore personal protective 
equipment including gown, gloves, and facemask. Researcher #1 would remove the test requisition form from the sam-
ple bag and verify that the patient demographic information on the form matched information listed on the specimen 
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tube. Upon completion of this verification, researcher #1 would write a unique serial tube number (1-88) in three lo-
cations: cap of the sample, on the sample tube itself, and the test requisition form. Researcher#1 would then place that 
numbered tube into the test tube rack in sequence. Tubes were racked in groups of 88 as the testing instrument used 
by the UofL-CPM analyzed 88 samples in each testing batch, in addition to the spaces reserved for controls. (Image 2)
At the same time researcher #1 is working in the BSC, researcher #2 would construct the specimen catalog. An elec-
tronically shared Excel spreadsheet process was used to develop that specimen catalog enabling real-time visual access 
for specimen location and quality monitoring. Data in the spreadsheet included: current date, time of the testing run, 
collection date of the specimen, tube number, REDCap identification number, name, date of birth, and a location for 
the barcode that would be provided. Researcher #1 would read aloud the patient’s name, date of birth, and write a tube 
number (1-88) on the cap of the specimen sample as well as the body of the sample. Researcher #2 entered those data 
elements into the specimen catalog spreadsheet. The tube number provided a way to identify any given tube if the tube 
was needed for additional testing. Following completion of the process, the researcher #2 would work with the quality 
reviewer to perform a quality crosscheck with the REDCap database and add the patient’s unique identifying number 
(assigned in REDCap) to the catalog. This would ensure that the patient specimen had been entered into REDCap and 
the specimen used for testing was correct (e.g., nasopharyngeal swab versus sputum). At this point, the specimen cata-
loging process was complete. The specimens were placed in a locked biohazard transport container and transported to 
a designated area for the UofL-CPM personnel to take possession of the samples for laboratory processing.
 
6. Assignment of the specimen barcode
The specimen barcoding process included application of a unique barcode identifier to each specimen tube. This 
unique barcode with human readable characters identified the location of the sample on the test plate and linked the 
result to the individual patient. The specimen barcoding process required two laboratory technicians. The barcoding 
process began after the LCPS team provided the completed specimen catalog spreadsheet to the UofL-CPM lab per-
sonnel. This important communication process confirmed that the sample tubes were prepared, a quality review of the 
REDCap data entry had been completed and the catalog spreadsheet had been completed. Once verified, the barcoding 
process could begin. Laboratory technician #1 would work under the BSC in the laboratory area where they would 
pick up the first tube from the rack and call out the name on the tube. This would enable technician #2 to crosscheck 
the specimen catalog and apply the barcode to the specimen tube and the catalog sheet. (Image 3) This would ensure 
that the same bar code was assigned to the patient specimen tube, the catalogue sheet, and to the aliquot from that 
specimen tube that was placed into the test well. This process continued until all 88 specimen tubes had been barcod-
ed, the barcodes entered on the cataloging sheet, and the aliquot placed into the test well. The specimen catalog sheet 
Image 2. Researchers Racking Tubes and Cataloging Specimen for Processing.
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was then given to LCSP personnel who then scanned the barcode from the specimen catalogue into REDCap (Images 
4 and 5). The alphanumeric barcode would then be visible in REDCap as shown in Figure 4. Following completion of 
this process, two quality team members performed a review of the barcode scans for each specimen in the run to ensure 
accuracy of the tube assignment and visibility of the barcode in REDCap.
  
7. Specimen testing
After barcoding, the UofL-CPM staff assumed responsibility for the specimen and testing began in a biosafety level 
2 laboratory with an enhanced biosafety practice. This area was chosen as biosafety cabinets and space were readily 
available. The two UofL-CPM personnel responsible for the specimen processing wore gowns, gloves, and facemasks. 
UofL-CPM virology personnel opened specimen samples under a BSC, obtained an aliquot from the specimen tube, 
and pipetted it into the testing block. Samples were tested for SARS-CoV-2 with a real-time-PCR assay detecting viral 
RNA.  Samples (up to 100 µL) were treated with Trizol reagent, which inactivated the virus and released RNA from the 
sample. Then, the total RNA in the sample was extracted and purified using a magnetic beads-based method.
RNA extraction was performed using laboratory automation (Tecan Evo100 with MCA96) with a script developed 
in-house. Eighty-eight total samples were processed as a batch in a 96-well plate along with four negative controls 
(healthy volunteers) and four positive controls (viral RNA extracted from in vitro culture). Detection of viral RNA in 
the extracted RNA was performed with the real-time PCR technology with the primer/probes (2019-nCoV CDC EUA 
Kit), developed by CDC and manufactured by IDT using a one-step master mix (TaqPath CG, Thermofisher). Real-time 
RT-PCR was conducted with QuantStudio7Pro in a 384-well plate format. The human RNAse P gene was used for an 
internal control to ensure human cells were present and to detect any sample inhibition that might be present. A Ct val-
ue less than 39 was considered as positive for the target.  While one technician worked with the specimen, the second 
technician monitored placement of the aliquot in the test well and assured the assigned bar code was linked to the cor-
responding patient in the test instrument. Once completed, the original sample tubes were returned to the refrigerated 
Image 3. Assignment of Barcode.
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Image 4. Scanning Barcode into REDCap.
Image 5. Specimen Catalog with Barcode.
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area for pickup by LCSP personnel. 
8. Integration of results from the testing instrument to the specimen database
After each testing cycle, the instrument recorded results that were analyzed by the principal virologist. Once satisfied 
with the quality of the results and test process, the results were sent in an Excel spreadsheet via internal secured email 
to the LCSP biostatistics and informatics personnel for uploading into REDCap. This upload linked individual results 
to their unique barcode and populated the Results section in REDCap for each patient. 
9. Analysis of test results
LCSP personnel reviewed the test result information provided by the virologist using the specimen catalog spreadsheet 
to verify that each result had linked to the correct patient barcode. REDCap was programmed to assign a completion 
status for all results identified as “negative” or “invalid”. Results identified as “inconclusive” would await another run 
using the original specimen (not the aliquot). A second “inconclusive” result would be finalized. All results finalized as 
“inconclusive” or “invalid” were communicated to the submitting facility so they could make the clinical determination 
as to whether a new specimen should be collected and resubmitted for testing. All “positive” results required manual 
entry into REDCap and completion of result verification as a final check to ensure there were no positive results en-
tered in error. The completion work was done by one of the Infectious Diseases faculty members with a quality partner 
to prevent patient/barcode identification errors. (Figure 6)
10. Communicating test results
The primary purpose of the surveillance program was to identify patients with and without disease so healthcare per-
sonnel could evaluate the necessity for isolation, use of personal protective equipment, and healthcare worker occupa-
tional exposure assessment. Therefore, it was critical to ensure results were shared promptly with individuals empow-
ered to make local decisions. Results were reviewed as the principal virologist released them. This process occurred 
at least once each day and sometimes twice if multiple testing runs occurred. Results were shared via telephone with 
the Chief Medical Officer of each hospital facility the day results were received. A written report with a cumulative list 
of all patients tested from that facility was emailed the following day using a secured and encrypted process. Included 
in that report was a cover page with an explanation of the test interpretation. This helped recipients understand what 
action was indicated in the event the result was noted as “invalid” or “inconclusive”. A summary report was also sent to 
the Kentucky Department for Public Health and the local health departments (e.g., Louisville Metro Public Health and 
Wellness, Floyd and Clark counties in neighboring southern Indiana). Excel files of patient results were also sent to the 
laboratory contact at each facility so they could integrate results into their separate electronic health record systems. 
Individual patient reports were not provided. By week five of the project, a REDCap data portal was developed with 
access provided to each facility submitting patient samples for testing. This portal access was made available to a point 
person at each facility enabling them to have real-time access to finalized test results. (Figure 8)
11. Quality measures
Ensuring quality at every step in the process involved identifying activities prone to error (e.g., manual data entry) as 
well as activities that were subject to errors of high consequence (e.g., misidentification of specimen, barcoding error). 
Each step in the process was evaluated to determine possible errors and a corresponding approach for quality moni-
toring. Figure 9 provides a summary of the quality indicators for each process step. Specific personnel were assigned 
to the quality measurement function, each serving as an independent evaluator of the process. These personnel were 
trained in each step of the process and helped craft the indicators. Quality reports were developed and shared with 
the LCSP teams as a way of tracking process errors as well as identifying opportunities for quality improvement and 
efficiencies.
Organizational Capacity
The CERID research enterprise provides the framework and support necessary for a robust program focused on pop-
ulation-based clinical research capable of studying health conditions present in patients receiving care in hospitals, 
long-term care facilities, and outpatient settings. The CERID enterprise structure enabled quick access to trained per-
sonnel and organizational capacity. Having this structure in place enabled the rapid implementation of a surveillance 
team and process to address the COVID-19 pandemic. 
Operationalizing the surveillance process incorporated use of each component of the CERID enterprise. A brief de-
scription of those units and their responsibilities shown in Figure 1 are described below:
The Data Management, Biostatistics, and Informatics Units were responsible for working together to develop the initial 
REDCap database and respond to improvements that resulted over the first five weeks of its use.  These three groups 
worked together to develop reports and reporting processes as well as respond to technologic requests from hospitals, 
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Figure 8. REDCap Database Portal View.
long term care facilities and public health concerning real-time, read-only data access. This real time access required 
that individual portals be developed so facilities could see only their data while public health officials were able to ac-
cess all data. 
The Implementation Unit was responsible for surveillance activities including specimen retrieval, data entry, catalog-
ing, and barcoding. This group consisted of personnel with specific training in clinical research and all aspects of a 
standardized operational approach. 
Laboratory Unit personnel possessed expertise in the handling and management of clinical and research specimens, so 
they were quickly able to transition their work from clinical research studies to assisting with specimen management 
and handoff to the UofL-CPM testing team. These personnel were also critical in developing an understanding of good 
laboratory practices as are present in the ID Division Reference Laboratory. In addition, these personnel provided the 
necessary expertise in understanding test results, their limitations, and approaches for providing useful information 
back to the participating facilities and healthcare personnel. 
The Biorepository Unit was responsible for developing the process to track and maintain all specimen in the event it 
was necessary to retest. This unit also managed the process for freezing all positive specimens for validation or subse-
quent re-testing. The REDCap database provided the opportunity to document and catalogue precise specimen loca-
tion for easy retrieval. (Figure 5)
Members of the Quality Assurance Unit were responsible for identifying steps in the process where error could occur. 
This included identification of steps that were prone to error and situations where error occurred or where there was 
a ‘near miss’. This team provided reports of those occurrences back to the team leader and each were addressed im-
mediately. This work involved process change (e.g., a numbering system added to tubes), error prevention (e.g., imple-
menting a 3-day save the tube procedure), and identifying near miss situations (e.g., individual specimen identification 
instead of multiple samples under a single REDCap identification number). With any change, staff were re-trained.  
The Community and University Outreach Units worked with researchers across the University of Louisville campuses 
and the community to identify their areas of expertise and interest in surveillance program participation as well as de-
signing research questions. Researchers in the Speed School of Engineering worked to develop products that could use 
the 3D printing capability to address care-related capacity such as production of face shields for nurses and printing of 
an alternative swab in light of the shortages in that critical supply. 
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/10 13
ULJRI Endemic Human Coronaviruses in Hospitalized Adults with Community-Acquired Pneumonia in the City of Louisville, Kentucky
The Medical Writing Unit and the Peer-Review Journals Unit continued their responsibility for disseminating knowl-
edge gained as part of the COVID-19 response. As new information was learned regarding the process, a mentored writ-
ing and publication process began with articles submitted for peer-review in both the Journal of Respiratory Infections 
and the Journal of Refugee and Global Health.  
Members of the Marketing Unit served as the communication link with local media, community partners, and public 
health so there was ongoing awareness of activities and findings. For example, this Unit was responsible for working 
with radio, television, and other social media connections interested in the surveillance operation and findings. 
Coordination of all personnel activities occurred within the Administration Unit of CERID. This group managed per-
sonnel decisions, addressing University quarantine and activity ‘pauses’, and communication with all University divi-
sions and leadership. Reassignment of job responsibilities, additional training and competence documentation consti-
tuted the majority of the responsibilities handled by this unit.
The Financial Unit was critical in ensuring that costs associated with the surveillance program were captured and 
managed. An initial investment of $500,000 by the University of Louisville President and the Executive Vice President 
for Research and Innovation enabled the operation to begin while community and grant support was explored and 
Process Step Quality Indicators
1. Test instrument validation and 
result verification
1A. Concordant results using two different test methods; one in CLIA-certified lab and 
one in research lab
2. Database development 2A. Manual entry restricted to demographic section
2B. Dropdown options available for all data items
2C. Portal access can be developed
2D. Individual facility reports
2E. Barcode capability
2F. Result import acceptable
2G. Phone friendly iOS and Android
3. Specimen movement from 
hospitals to the testing site
3A. Packaged appropriately for transport
3B. Test request form accompanying each specimen
3C. Test request form and specimen match
3D. Specimen labelled
3E. Specimen label legible
4. Data entry 4A. Correct spelling of patient name
4B. Correct date of birth
4C. Specimen assigned to correct facility
4D. Correct specimen type
4E. Identity of data entry personnel
5. Cataloging the specimen for 
movement to the laboratory for 
processing
5A. Appropriate PPE worn by personnel
5B. All work performed in biosafety cabinet
5C. Specimen tubes numbered
5D. Specimen tubes in rack
5E. Catalog completed with all data elements entered
5F. Catalog data elements accurate
5G. Tubes transported to CMP refrigerator in closed container to await testing
5H. PPE removed, placed in biohazard bag, hand hygiene by personnel
5I. Specimen catalog placed with tubes in CPM refrigerator to await barcode placement
6. Assignment of the specimen 
barcode
6A. Barcode placed on specimen catalog sheet by CPM personnel
6B. Barcode sheet retrieved by LCSP personnel
6C. Barcode scanned into REDCap
6D. Barcode verified to ensure capture in REDCap and on correct patient
6E. Multiple barcode acceptance
7. Specimen testing 7A. Process supports standard test run times
7B. Result concordance with parallel testing
7C. Definitive results
7D. Process demonstrates accepted good laboratory practices
8. Integration of results from 
the testing instrument to the 
specimen database
8A. Imports accepted by Excel
8B. Data imports allowing finalization of select results
9. Analysis of test results 9A. Definitive results
9B. Reliable barcode links
10. Communicating test results 10A. Direct communication with hospital chief medical officers
10B. Direct communication with public health officials
10C. Direct communication with facility point person
10D. Portal available with file download options
10E. Printed report option
Figure 9. Quality Indicators for Each Process Step.
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/10 14
ULJRI Endemic Human Coronaviruses in Hospitalized Adults with Community-Acquired Pneumonia in the City of Louisville, Kentucky
captured. This Unit was also responsible for providing ongoing reports concerning the financial impact on the entire 
CERID enterprise, including current research outside of COVID-19 response. 
Discussion
The UofL CERID leadership team set specific goals for the LCSP that included: 1) increasing the COVID-19 testing ca-
pacity for Kentucky and southern Indiana (Kentuckiana); 2) providing an ability to study the burden of the COVID-19 
pandemic on the local population; and 3) supporting healthcare facilities as they developed local policies guiding their 
responses to COVID-19 in patients and healthcare workers. 
Between late February and early March, there was considerable concern regarding a lack of COVID-19 testing capac-
ity in Louisville and across Kentucky. Without access to testing, the healthcare infrastructure and healthcare workers 
remained at tremendous risk. In Louisville, healthcare is a primary industry with 10 area hospitals, more than 45 long-
term care facilities, headquarters for health insurers and pharmaceutical companies, and specialty centers for cancer, 
HIV, and trauma care. This level of healthcare industry present in the community led to recognition of the importance 
of protecting this element of the workforce and economy by early testing and disease recognition. As the LCSP pro-
gram was conceptualized then implemented, with the financial support of UofL President Bendapudi, all aspects of 
the program were clearly focused on healthcare facilities and healthcare workers. The University provided space and 
CERID assumed responsibility for identifying and training the necessary personnel for activities within the scope of 
practice and competence. For testing capacity, specialists in the area of virology with expertise in high-capacity testing 
platforms helped define the new process. Research meetings began with outreach across the University along with 
development of white papers and grant submissions. As an example, the focus on healthcare personnel surveillance 
and testing was submitted to the Centers for Disease Control and Prevention on March 25, just 12 days after LCSP im-
plementation.  Broad and transparent collaboration and sharing occurred to encourage engagement across the Univer-
sity campus communities. With the breadth of activities, there have been challenges at every step. During this time of 
healthcare, economic, and social disruption, it has been challenging to infuse a sense of normalcy. Reliance upon exist-
ing systems has been challenging, but using existing relationships and professional connections have enabled progress 
and quality outcomes. The real consequences of using a new process for COVID-19 testing, along with shortages in the 
supply chain, and using just-in-time training for new personnel to obtain specimens, were challenges to understanding 
all the results and conveying them in the context of clinical relevance.  
After six weeks of operation, more than 5000 samples were tested with more than 730 positive patients and healthcare 
workers being identified. Samples were received from fifteen hospitals and seventeen long-term care facilities in the 
Kentuckiana area. The operation involved faculty time from Infectious Diseases, Laboratory Medicine, Microbiology, 
Virology, and Research & Innovation. More than 30 CERID personnel played a role in the processes, in addition to 
staff representing other areas of the University such as building security, maintenance and Environmental Health and 
Safety. The operational costs, not including laboratory supplies and laboratory personnel, have been approximately 
$50,000 per week. 
There are several lessons learned from this process that can be of help to others as they address the challenges posed 
by the COVID-19 pandemic. First, the process is applicable to other testing methods beyond high-capacity testing. 
Most of the same steps outlined here can help with traditional laboratory processes when test request capacity exceeds 
historic capabilities. Second, success with a new approach during a time of chaos and upheaval can be achieved when 
there is an ability to rely upon existing systems and staff knowledge. Experiences with research processes, database 
development, just-in-time training, attention to detail, and innovation were critical elements. Third, developing a vital 
public health response requires an ability to seek and nurture new partners with shared interests.  For the LCSP team, 
methods to best address the ongoing challenges of the COVID-19 pandemic required that existing relationships and 
capacities be maximized and there be a continuous focus on supporting the healthcare infrastructure and safety of the 
healthcare workforce. 
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